Calithera Biosciences Reports Phase I Data for CB-839 in Patients With Hematological Malignancies at the 57th American Society of Hematology Annual Meeting
Sun December 6, 2015 10:26 AM|GlobeNewswire | About: CALA
First results of CB-839 dosed in combination therapy
Promising clinical activity with early signs of biologic activity, tolerability, and durability
SOUTH SAN FRANCISCO, Calif., Dec. 06, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, announced that clinical and preclinical data from its lead product candidate CB-839, a first-in-class glutaminase inhibitor was presented today at the 57thAmerican Society of Hematology Annual Meeting (ASH), in Orlando, Florida. The data demonstrated the clinical activity, tolerability and unique mechanism of action of CB-839 in patients with acute myeloid leukemia (AML) and multiple myeloma.
We are encouraged by the promising clinical activity of CB-839 as a single agent in AML, and early tolerability and preliminary signals of efficacy in combination therapy in multiple myeloma, said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera. We are actively enrolling six combination expansion cohorts of CB-839 in solid and hematological malignancies and look forward to presenting additional combination data in 2016.
CB-839 in Multiple Myeloma
Dr. Dan Vogl from the University of Pennsylvania presented a poster titled, Phase I study of CB-839, a first in class glutaminase inhibitor in patients with multiple myeloma and lymphoma, (Abstract #3059). As of November 9, 2015, 23 multiple myeloma patients had been treated, including 14 treated with CB-839 as a monotherapy, and nine patients treated in combination with either dexamethasone (n=5) or pomalidomide and dexamethasone (n=4). The majority of patients had received at least four prior lines of therapy. In the monotherapy cohort, the best response was stable disease, which was reported in seven patients, including one patient who has remained on study for over seven months. The first patient to receive the CB-839 plus pomalidomide and dexamethasone combination has had a clinically significant reduction in myeloma markers, including urine M-protein and serum free light chain. Three of 14 (21%) monotherapy patients experienced Grade 3 events suspected to be related to CB-839, and one dose limiting toxicity (DLT) of Grade 4 neutropenia deemed possibly related to CB-839 occurred in the pomalidomide and dexamethasone combination group. No patients discontinued due to adverse events.
CB-839 in Acute Myeloid Leukemia
Dr. Eunice Wang from Roswell Park Cancer Institute presented a poster titled, Phase I study of CB-839, a first in class, orally administered small molecule inhibitor of glutaminase in patients with relapsed/refractory leukemia, (Abstract #2566). As of November 9, 2015, 26 acute leukemia patients had been treated including 24 with AML. This represents an update from the data presented June 11, 2015 at the European Hematology Association. All patients were relapsed and/or refractory, with 61% of patients treated with two or more prior therapies, and 23% of patients treated with prior allogeneic transplant. The mean age of patients was 75 years. Oral CB-839 was administered continuously in 21-day treatment cycles from 100 to 1000 mg three times daily (n=16), or twice daily (n=10). The 24 AML patients included two IDH1 and three IDH2 mutant AML patients. One patient achieved a complete response in the bone marrow with incomplete recovery of peripheral counts (CRi) and remains on therapy over 16 months. Five of 26 efficacy-evaluable patients across dose levels remained on therapy for at least 4 cycles (12 weeks), and up to 23+ cycles (>16 months). There were no DLTs identified and no patients discontinued due to adverse events.
In addition, Calithera and their collaborators presented two preclinical posters that provide the rationale for use of biomarkers of CB-839 in multiple myeloma, and elucidate the role of glutamine in AML. Details for the presentations are as follows:
Metabolomic, Proteomic and Genomic Profiling Identifies Biomarkers of Sensitivity to Glutaminase
Abstract: #1802
Andrew L. MacKinnon, Ph.D., Calithera Biosciences (CALA)
Role of Glutamine in Metabolic and Epigenetic Reprogramming in AML
Abstract: #2559
Juliana Velez Lujan, Ph.D., University of Texas MD Anderson Cancer Center
AI
